Generics Hikma Pharmaceuticals will sell the rights and assets for two generic drugs, and relinquish its US marketing rights to a third generic drug, in order to settle US Federal Trade Commission charges that Hikma’s proposed acquisition of Roxane from German family-owned pharma major Boehringer Ingelheim would likely be anticompetitive. 29 February 2016